RSS
ADLR's PDUFA date for Entereg (Postoperative Ileus) is May 9th 2008. Will the FDA approve the drug?
AnswerVotes
Yes, full market approval6
No, FDA will not approve2
Will receive approvable letter3
Cast your vote now!


premium database
Username:
Password:

Not A Member?
Take the Tutorial

Log In to Trial View
Sign In


Biotech News
Genentech has revised its timeline forecast for availability of final efficacy and safety results for the C-08 study from 2010 to 2009. The study, involving... An abstract submitted to the Annual Meeting of the American Society of Clinical Oncology (ASCO), entitled "Phase Ia Safety and Pharmacokinetic Study of Oral NV-196... Array BioPharma and AstraZeneca announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886). The trials, which will begin during the second half... Omrix Biopharmaceuticals announced that Larry Ellberger was named Chairman of the Board of Directors and Pamela McNamara was elected a Director at the Company's 2008... Valeant Pharmaceuticals announced that the Food and Drug Administration (the FDA) has entered an administrative order in the public interest to stay the approval of... Sepracor announced that its Board of Directors has approved the appointment of Robert F. Scumaci as Executive Vice President and Chief Financial Officer. Mr. Scumaci... Human Genome Sciences announced that Kevin P. McRaith has joined the Company as Vice President, Hepatology Franchise. Mr. McRaith, formerly Vice President, Sales & Marketing-... Theratechnologies announced a strategic agreement with both the Massachusetts General Hospital ("MGH") and Dr. Steven Grinspoon to explore the use of tesamorelin in relative growth... Allos Therapeutics reported interim response and safety data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory... MorphoSys AG announced that at the Company's annual shareholder meeting on Wednesday, May 14, 2008, its shareholders confirmed the reappointment of Dr. Gerald Moller, Dr....

Biotech Milestones
Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to... Amarillo Biosciences announced that the U.S. Food and Drug Administration has allowed the Investigational New Drug (IND) application submitted by the Company to test its... Medivation announced that, based on its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the Company plans to begin a pivotal confirmatory... DURECT announced positive results from a Phase IIa clinical trial for ELADUR, DURECT's proprietary investigational transdermal pain patch. In this study of patients suffering from... Auxilium Pharmaceuticals completed patient enrollment in the Company's second U.S. phase III pivotal trial (CORD I) and its Australian phase III study (CORD II) of... Pain Therapeutics and King Pharmaceuticals announced positive results of a Phase III study of Remoxy(tm) in patients with chronic pain. Over 400 patients with osteoarthritis... DURECT announced that the pivotal Phase III trial for Remoxy had successfully met its primary endpoint (p<0.01) that was prospectively defined by the U.S. Food... Phase 2 data expected in 2Q08. ADVENTRX Pharmaceuticals has completed patient enrollment in its Phase 2 clinical trial of ANX-510, or CoFactor, for the treatment... Acorda Therapeutics announced results from a thorough QT study of Fampridine-SR. This study evaluated the potential to cause an increase in the electrocardiographic QT interval.... The Medicines Company announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's supplemental new drug application (sNDA) for a modified dosing... Phase 1. Phase 2 is expected to begin in 2Q08.... DOR BioPharma announced that patient enrollment is commencing in a randomized, double blinded, placebo controlled Phase 2 clinical trial of orBec for the prevention of... Theratechnologies announced that the last patient has completed 26 weeks of treatment in the confirmatory Phase 3 trial testing tesamorelin in HIV-associated lipodystrophy. The Company... Cortex Pharmaceuticals was notified by the German regulatory agency which approves the use of narcotic drugs that it can proceed with the trial which will... Wyeth Pharmaceuticals and Progenics Pharmaceuticals announced preliminary findings from the first of two phase 3 clinical trials of intravenous methylnaltrexone being evaluated for the management... Eurand announced that the New Drug Application (NDA) for Zentase (EUR-1008) was accepted and has been granted priority review by the United States Food and... Labopharm completed North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001) achieved statistical significance for the primary efficacy... Arena Pharmaceuticals announced positive results from a single dose Phase 1a clinical trial of APD791 and the initiation of a multiple dose Phase 1b clinical... GTC Biotherapeutics announced that ATryn has completed enrollment in the pivotal study for the treatment of patients with hereditary antithrombin deficiency, or HD, undergoing high-risk... Favrille announced that it has reached the data cutoff date for the Company's Phase 3 registration trial of Specifid (mitumprotimut-T, formerly FavId) following Rituxan in... Active Biotech AB presented the final results of the previously reported clinical Phase I study of the cancer project ANYARA in combination with Taxotere in... Genaera announced that the investigational new drug (IND) application submitted to the US Food and Drug Administration (FDA) for trodusquemine (MSI-1436) in type 2 diabetes...



Company Profile

Biotech Watch LLC was established September 3rd 1997 to be the premier site for biotechnology information services. BiotechWatch provides access to a continuously updated interactive database that follows such parameters as products under development, status of clinical trials, cash on hand, burn rate, and upcoming clinical milestones for over 5000 products from more than 600 biotech and medical device companies. Subscribers can use any of more than fifteen search parameters to identify companies of interest.

Valuations of most biotech companies are determined by the perceived value of their technology, the success of their clinical trials, the breadth of the clinical market being addressed, their likely competitors, the strength of the strategic partnerships they have forged, the depth of their research and clinical pipelines, and their current financing. The staff of BiotechWatch have created this database to more carefully monitor these parameters across the biotechnology sector to allow investors and industry professionals to make the most informed decisions possible.

The obvious advantage of using the BiotechWatch database to follow the biotech industry is the ability to search or sort for companies and clinical trials that have specific characteristics. The database can be used as a basic research tool to access information such as cash-on-hand, milestones, trading volume, and products under development for a specific disease or medical indication. These latter parameters provide information regarding potential competitors and/or partners in specific development areas. As the timeliness of this information is of paramount importance, the BiotechWatch staff updates all clinical trial information daily and financial information such as stock price, market cap, shares outstanding, 52 week high and low and their derivative values are updated every 5 minutes.

We have gone to every effort to make this database as intuitive, helpful, comprehensive, and timely as possible. We welcome your input and suggestions to make this the best site possible.

Alfred Mansour, Ph.D.

Dr. Alfred Mansour, a founder and CEO of Biotech Watch LLC, has extensive experience in the biotech industry. Dr. Mansour has served as President of Pharmaco Genesis Corporation, a biotechnology consulting firm, and Vice President of Biotechnology Analysis at BioDiligence Partners, Inc. which conducts technical due diligence for biopharmaceutical company management and investors. In addition to his responsibilities at Biotech Watch LLC, Dr. Mansour has been a Senior Analyst for the Brown Simpson Asset Management Fund, a New York City based $500M fund that invests in publicly traded biotechnology and Internet companies. Dr. Mansour' s career includes extensive research at the Mental Health Research Institute at The University of Michigan. During that time he shared two prestigious awards: the A.E. Bennett Award (1991) from the Society of Biological Psychiatry for his contributions to the field of psychiatry and schizophrenia, and the Discovery Award (1994) for his work in elucidating the molecular biology of endogenous opiate receptor systems in the central nervous system. Dr. Mansour has served on numerous scientific committees including the American College of Neuropsychopharmacology and the National Institute of Drug Abuse's Neuroanatomy and Neurophysiology Review Subcommittee. Dr. Mansour is a member of the American College of Neuropsychopharmacology, the New York Academy of Sciences, the American Association for the Advancement of Science, the Society for Neuroscience and Sigma Xi, the national psychology honor society. Dr. Mansour has been broadly published including publications in the distinguished journals Trends in Neuroscience, the Journal of Neuroscience, Brain Research, the Journal of Pharmacology and Experimental Therapeutics, and The Proceedings Of The National Academy of Sciences. In addition, he has published over 20 chapters in scientific/medical texts. Dr. Mansour received his B.A. cum laude from Yeshiva University in 1979 and his Ph.D. with high honors from The University of Michigan in 1984.